FDA issues draft guidance on inactive ingredient database
The US Food and Drug Administration (FDA) recently released a draft guidance for public consultation providing recommendations for drugmakers on using the agency’s inactive ingredient database (IID) during drug development. The IID is an online repository of information about excipients used in FDA-approved products and serves as a replacement for the inactive ingredient guides the agency began disseminating in the late 1980s.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063